Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Phase 1B/2 Study of Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic Biliary Tract Cancer.

NCT02992340 is registered in ClinicalTrials.gov with ASLAN Pharmaceuticals as lead sponsor.

NCT NCT02992340
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02992340 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Phase 1B/2 Study of Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic Biliary Tract Cancer.
Lead sponsor
ASLAN Pharmaceuticals
Phase
Phase 1/2
Overall status
Terminated
Start date
December 13, 2016
Completion date
November 24, 2020
Enrollment
204 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancer